David P. Schenkein, MD | Authors

High-Dose Therapy With Stem-Cell Transplantation in the Malignant Lymphomas

December 01, 1999

Approximately 35,000 stem (progenitor)-cell transplants are performed annually worldwide, with an estimated yearly growth rate of between 10% and 20%.[1] Non-Hodgkin’s lymphoma remains the second most common indication for stem-cell transplantation, and Hodgkin’s disease ranks approximately seventh overall.[1]